Trypanosomatid parasites are the infectious agents causing
Chagas disease, visceral and
cutaneous leishmaniasis and human
African trypanosomiasis. Recent work of others has implicated an
aldo-keto reductase (AKR) in the susceptibility and resistance of Trypanosoma cruzi to
benznidazole, a drug used to treat
Chagas disease. Here, we show that TcAKR and homologues in the related parasites Trypanosoma brucei and Leishmania donovani do not reductively activate monocyclic (
benznidazole,
nifurtimox and
fexinidazole) or bicyclic nitro-drugs such as
PA-824. Rather, these
enzymes metabolise a variety of toxic ketoaldehydes, such as
glyoxal and
methylglyoxal, suggesting a role in cellular defence against chemical stress. UPLC-QToF/MS analysis of
benznidazole bioactivation by T. cruzi cell lysates confirms previous reports identifying numerous drug metabolites, including a dihydro-dihydroxy intermediate that can dissociate to form N-benzyl-2-guanidinoacetamide and
glyoxal, a toxic
DNA-glycating and cross-linking agent. Thus, we propose that TcAKR contributes to
benznidazole resistance by the removal of toxic
glyoxal. In addition, three of the four
enzymes studied here display activity as
prostaglandin F2α synthases, despite the fact that there are no credible
cyclooxygenases in these parasites to account for formation of the precursor
PGH2 from
arachidonic acid. Our studies suggest that
arachidonic acid is first converted non-enzymatically in parasite lysates to (PGH2-like) regioisomers by
free radical-mediated peroxidation and that AKRs convert these
lipid peroxides into
isoprostanes, including
prostaglandin F2α and 8-iso-prostaglandin F2α.